The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 afucosilado con bendamustina destinada al tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo B-Ly1 humanizado afucosilado y bendamustina.